Exelixis (EXEL) announced that the European Commission (EC) has approved its CABOMETYX (cabozantinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF)-targeted therapy. The approval was expected following a positive Ad Comm vote in July. The FDA approved the RCC indication in April.